Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. United Therapeutics Corp shares valued at $1,739,525 were purchased by ROTHBLATT MARTINE A on Oct 02 ’25. At $434.88 per share, ROTHBLATT MARTINE A acquired 4,000 shares.
Also, ROTHBLATT MARTINE A sold 4,000 shares, netting a total of over 1,739,525 in proceeds. Following the sale of shares at $434.88 each, the insider now holds 130 shares.
Before that, ROTHBLATT MARTINE A had sold 4,000 shares from its account. In a trade valued at $1,701,797, the Chairperson & CEO traded United Therapeutics Corp shares for $425.45 each. Upon closing the transaction, the insider’s holdings decreased to 4,000 shares, worth approximately $57647.2.
As published in their initiating research note from RBC Capital Mkts on September 26, 2025, United Therapeutics Corp [UTHR] has been an Outperform and the price target has been revised to $569. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in early June. As of April 25, 2025, Wells Fargo has decreased its “an Overweight” rating to a “an Equal weight” for UTHR. Earlier on April 21, 2025, BofA Securities upgraded its rating. Their new recommendation was “a Neutral” for UTHR stock which previously was a “an Underperform”.
Analyzing UTHR Stock Performance
On last trading session, United Therapeutics Corp [NASDAQ: UTHR] rose 1.20% to $443.44. The stock’s lowest price that day was $432.605, but it reached a high of $444.52 in the same session. During the last five days, there has been a surge of approximately 4.24%. Over the course of the year, United Therapeutics Corp shares have jumped approximately 23.74%. Shares of the company reached a 52-week high of $444.57 on 10/02/25 and a 52-week low of $266.98 on 04/09/25.
Support And Resistance Levels for United Therapeutics Corp (UTHR)
According to the 24-hour chart, there is a support level at 435.81, which, if violated, would cause prices to drop to 428.18. In the upper region, resistance lies at 447.82. The next price resistance is at 452.19. RSI (Relative Strength Index) is 69.23 on the 14-day chart, showing neutral technical sentiment.
Is United Therapeutics Corp subject to short interest?
Stocks of United Therapeutics Corp saw a sharp steep in short interest on 2025-09-15 dropping by 71212.0 shares to 2.78 million. Data from Yahoo Finance shows that the short interest on 2025-08-15 was 2.86 million shares. A decline of -2.56% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.12 of the overall float, the days-to-cover ratio (short ratio) decline to 3.12.
Which companies own the most shares of United Therapeutics Corp (UTHR)?
In terms of United Therapeutics Corp share price expectations, FactSet research, analysts set an average price target of 544.5 in the next 12 months, up nearly 24.26% from the previous closing price of $438.18. Analysts anticipate United Therapeutics Corp stock to reach 580 by 2025, with the lowest price target being 314. In spite of this, 7 analysts ranked United Therapeutics Corp stock as Buy at the end of 2025. On July 11, 2024, Morgan Stanley assigned a price target of “an Equal-weight” to the stock and downgraded coverage with a $321.
